We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Updates Checklists for Accepting 510(k)s

FDA Updates Checklists for Accepting 510(k)s

Clinical
August 7, 2015

With an eye toward encouraging quality applications for review, the FDA has provided an update on what information it needs from sponsors to determine whether a 510(k) submission meets a minimum threshold and thus may be accepted for substantive review.

Issued Aug. 4, the new FDA guidance updates a 2012 document and is intended to explain the refuse-to-accept policy for 510(k)s. As part this policy, the FDA reviews an application and within 15 calendar days should inform the company whether the submission is administratively complete or if additional elements are needed.

“In order to enhance the consistency of our acceptance decisions and to help submitters better understand the types of information FDA needs to conduct a substantive review, this guidance, including the checklists included in the appendices, clarify the necessary elements and contents of a complete 510(k) submission,” according to the document.

As part of the update, the agency has added guidance documents and other resources that industry may use when preparing regulatory submissions. It also has streamlined the checklists in the appendices covering traditional, abbreviated and special 510(k)s.

Some sections have been either eliminated or incorporated in other parts of the list. One change is the elimination of a section requesting companies include a form for each national or international standard referred to in the application to demonstrate substantial equivalence for traditional 510(k)s. That checklist adds to the section on sterilization, which now includes options for devices not requiring a sterility status, such as, software-only devices, and for those products whose sterility status is unclear.

The guidance, which goes into effect Oct. 1, will supersede three previous documents: 2012’s “Food and Drug Administration’s Refuse to Accept Policy for 510(k)s,” 1993’s “Premarket Notification (510(k)) Refuse to Accept Policy” and 1994’s “510(k) Refuse to Accept Procedures (K94-1) blue book memo.”

To read the guidance document, visit www.fdanews.com/081015-refuse-to-accept.pdf. — Elizabeth Hollis

Regulatory Affairs

Upcoming Events

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

  • 12May

    Extractables and Leachables: 101

  • 19May

    CDRH’s New Accreditation Scheme for Conformity Assessment: Impacts on Your Future Testing Plans and FDA Submissions

  • 25May

    How Can the Accelerated Availability of Pfizer-BioNTech’s COVID-19 Vaccine be Replicated?

  • 27May

    Evolving Clinical Trials: Continuing the Journey from Paper to Digital

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Fujifilm_Logo.gif

    Fujifilm Begins Late-Stage Trial of Avigan for COVID-19

  • CE mark

    DiaSorin’s 10-Minute COVID-19 Antibody Test CE Marked

  • WHO

    WHO Will Review Two COVID-19 Vaccines from China

  • CE mark

    Qiagen’s High Throughput COVID-19 Test Earns CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing